Sign in
Taking people in United StatesPhase 3

Fifth dose of VLA15 vaccine for Lyme disease in healthy people

Tests a fifth VLA15 vaccine dose against placebo in healthy people already given 4 doses.

Key facts

Who runs it
Pfizer
Where
Bangor, Burlington, Cortland, Duncansville, East Greenwich, Erie, Flemington, Horseheads, Pittsburgh, Sayre, Scottdale, Scranton, Smithfield, Uniontown, Winchester, and Worcester, United StatesSee the 19 sitesAlso in 1 other country, 3 sites
Trial code
Registry title
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
Status
Recruiting
Phase
Phase 3
People taking part
1,712 people, planned
Started
8 Apr 2026
Expected to end
4 Dec 2026
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • VLA15
  • Placebo
Record updated
6 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy people aged 7 years and older who already had 4 doses of the Lyme disease vaccine VLA15. They get a 5th dose or a saltwater shot.

Age
7 Years and older
Sex
All sexes can join
Disease stage
Healthy volunteers, based on medical history and the doctor's judgment
Earlier treatment
People must have received 4 doses of VLA15 in the C4601003 study. People cannot join after recent cancer treatment, blood or plasma products, immunoglobulins, systemic corticosteroids, drugs that weaken the immune system or blood thinners.
Biomarker or test result
A V7 blood sample from the earlier study must be available

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Allergy to vaccines or their parts, or other reasons a vaccine cannot be given
  • Blood clotting problems, weak immune system, bone marrow disorder or uncontrolled mental health conditions
  • Recent or current part in another interventional study
  • Staff of the study site or sponsor, or their direct family

This trial only enrols healthy participants. The registry sentence this rests on: * Participants who are healthy as determined by medical history and clinical judgment.

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Participants who are healthy as determined by medical history and clinical judgment
  • Participants willing and able to comply with all scheduled visits, IP receipt, and other procedures throughout the study
  • Able to provide Informed Consent
  • Participants must have received 4 doses of VLA15 in the C4601003 study, and have a V7 blood sample available

Who cannot take part

  • Recent or concurrent participation in a separate interventional study
  • Allergies or contraindications to vaccines or their components
  • Health issues including: blood clotting deficiencies, immunodeficiencies, bone marrow disorder, or uncontrolled psychiatric conditions
  • Receipt of therapies to treat malignancies, blood/plasma products and immunoglobulins, systemic corticosteroids and immunosuppressants, or anticoagulant therapy in recent medical history
  • Pregnant or breastfeeding participants
  • Staff or direct family of the study site staff and Sponsor

Where in United States

Also in 1 other country, 3 sites

  • Northern Light Eastern Maine Medical CenterBangor, United StatesNot yet recruiting
  • Northern Light Family Medicine and Residency CenterBangor, United StatesNot yet recruiting
  • The University of Vermont Medical Center Inc.Burlington, United StatesNot yet recruiting
  • Smith Allergy and Asthma SpecialistsCortland, United StatesTaking people
  • Altoona Center For Clinical ResearchDuncansville, United StatesTaking people
  • Velocity Clinical Research, ProvidenceEast Greenwich, United StatesNot yet recruiting
  • Allegheny Health and Wellness PavilionErie, United StatesTaking people
  • Central Erie Primary CareErie, United StatesTaking people
  • Hunterdon Medical CenterFlemington, United StatesNot yet recruiting
  • Smith Allergy & Asthma SpecialistsHorseheads, United StatesTaking people
  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)Pittsburgh, United StatesTaking people
  • Preferred Primary Care Physicians, Preferred Clinical Research-St. ClairPittsburgh, United StatesNot yet recruiting
  • Robert Packer HospitalSayre, United StatesTaking people
  • Frontier Clinical Research, LLCScottdale, United StatesTaking people
  • Northeast Clinical Trials GroupScranton, United StatesTaking people
  • Frontier Clinical Research, LLCSmithfield, United StatesTaking people
  • Preferred Primary Care PhysiciansUniontown, United StatesNot yet recruiting
  • Amherst Family Practice P.C.Winchester, United StatesNot yet recruiting
  • University of Massachusetts Chan Medical SchoolWorcester, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine.

Read full original descriptionShow less

This study is seeking participants who:

* are generally healthy and 7 years of age and older, * have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4. * are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners. * are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine.

All participants in this study will receive a total of 1 dose through a shot in the upper arm, either VLA15 or saline shot (saltwater).

The study will compare the experiences of people receiving the study vaccine or saltwater shot.

Participants will take part in this study for about 12 months. During this time, they will have 4 planned clinic visits. The clinic visits may include having a health check, giving a small amount of blood and getting the study vaccine or saltwater as a shot at the first visit.

The 4 groups in the trial

  • VLA15-1ATreatment being tested

    Participants will receive a single injection in the muscle (IM) of VLA15 at Visits 1, two years after their 4th dose of VLA15

    Treatment: VLA15

  • VLA15-1BPlacebo, for comparison

    Participants will receive a single injection in the muscle (IM) of Saline at Visits 1, two years after their 4th dose of VLA15

    Treatment: Placebo

  • VLA15-2ATreatment being tested

    Participants will receive a single injection in the muscle (IM) of VLA15 at Visits 1, one year after their 4th dose of VLA15

    Treatment: VLA15

  • VLA15-2BPlacebo, for comparison

    Participants will receive a single injection in the muscle (IM) of saline at Visits 1, one year after their 4th dose of VLA15

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A FIFTH DOSE OF 6-VALENT OSPA-BASED LYME DISEASE VACCINE, VLA15, IN HEALTHY PARTICIPANTS ≥7 YEARS OF AGE
Plain-language title
Fifth dose of VLA15 vaccine for Lyme disease in healthy peopleGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
6 May 2026